KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Return on Sales (2016 - 2025)

Historic Return on Sales for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to 0.05%.

  • Neogenomics' Return on Sales rose 400.0% to 0.05% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.15%, marking a year-over-year decrease of 300.0%. This contributed to the annual value of 0.15% for FY2025, which is 300.0% down from last year.
  • As of Q4 2025, Neogenomics' Return on Sales stood at 0.05%, which was up 400.0% from 0.14% recorded in Q3 2025.
  • In the past 5 years, Neogenomics' Return on Sales registered a high of 0.62% during Q2 2021, and its lowest value of 0.42% during Q1 2022.
  • Over the past 5 years, Neogenomics' median Return on Sales value was 0.16% (recorded in 2022), while the average stood at 0.15%.
  • As far as peak fluctuations go, Neogenomics' Return on Sales skyrocketed by 7000bps in 2021, and later plummeted by -9100bps in 2022.
  • Quarter analysis of 5 years shows Neogenomics' Return on Sales stood at 0.33% in 2021, then surged by 51bps to 0.16% in 2022, then surged by 44bps to 0.09% in 2023, then grew by 3bps to 0.09% in 2024, then skyrocketed by 42bps to 0.05% in 2025.
  • Its last three reported values are 0.05% in Q4 2025, 0.14% for Q3 2025, and 0.25% during Q2 2025.